Ads
related to: aclidinium bromide inhaler
Search results
Results from the WOW.Com Content Network
Aclidinium bromide is a long-acting, inhaled muscarinic antagonist (LAMA) approved in the United States in July 2012 [3] as a maintenance treatment for chronic obstructive pulmonary disease (COPD). [4] Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD. [5]
Aclidinium bromide/formoterol, sold under the brand names Duaklir and Brimica, is a fixed-dose combination medication for inhalation, used in the management of chronic obstructive pulmonary disease (COPD). [5] It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β 2 agonist. [3] [4]
Long-acting muscarinic antagonists, including tiotropium, aclidinium and umeclidinium, are indicated for severe asthma in maintenance treatment. [2] Muscarinic antagonists can reduce cholinergic bronchomotor tone, resulting in airway muscle relexation and bronchodilation. [8]
Forest Laboratories and Almirall announce commercial availability of Tudorza™ Pressair™ in US pharmacies New treatment for COPD now available in US pharmacies NEW YORK & BARCELONA, Spain ...
Forest Laboratories and Almirall Decide to Delay NDA Filing for Aclidinium/formoterol Combination NEW YORK & BARCELONA, Spain--(BUSINESS WIRE)-- Forest Laboratories, Inc. (NYS: FRX) and Almirall ...
Fluticasone furoate/umeclidinium bromide/vilanterol is only available as an inhaler, which generally contains thirty doses (one-month supply) of medicated powder for inhalation (except in the case of, e.g., sample products from the manufacturer or those produced specifically for hospitals [institutional formulations], which contain 14 doses). [4]
Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol ) [ 4 ] [ 5 ] and also as a triple-therapy ...
with umeclidinium bromide: Anoro Ellipta. Umeclidinium bromide is a long-acting muscarinic antagonist. [14] This combination was approved by the FDA on December 18, 2013 [15] for the long-term maintenance treatment of COPD. On March 28, 2014, it was approved in European countries [16] and in Russia [17] under the same trade name.
Ads
related to: aclidinium bromide inhaler